Universal Ibogaine Inc (IBO) Fair Value & Analysis
Healthcare · CA · Market cap C$1.6M
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Price vs Fair Value (12 months)
12‑month range C$0.0050 – C$0.0350 · fair‑value band C$0.0100 – C$0.0200 · the C$0.0050 price screens below the C$0.0100 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Universal Ibogaine Inc (IBO) currently trades at C$0.0050, while our model-based Fair Value estimate is C$0.0100 — implying the stock looks roughly 100.0% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Universal Ibogaine Inc generated revenue of C$2.1M at a net margin of -71.7%. Revenue grew 30.6% year over year. Net debt stands at C$2.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Universal Ibogaine Inc reported revenue of C$2.3M in FY2024 versus C$0 in FY2020. Reported net income was −C$2.1M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Universal Ibogaine Inc (IBO) undervalued?
What is the fair value of IBO?
What is the quality score of IBO?
What is the revenue of Universal Ibogaine Inc (IBO)?
What is the net profit margin of IBO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.